Hematopoietic Cell Transplantation for MHC Class II Deficiency

Area of Science:

• Immunology
• Genetics
• Pediatrics

Background:

• Major histocompatibility complex (MHC) class II deficiency is a rare, fatal primary combined immunodeficiency.
• It impairs antigen presentation and CD4+ T-lymphocyte maturation, leading to severe infections.
• Diagnosis relies on absent MHC class II molecule expression.

Purpose of the Study:

• To review the current understanding and management of MHC class II deficiency.
• To highlight advancements in hematopoietic cell transplantation (HCT) for this condition.
• To emphasize the need for multi-center studies on long-term outcomes post-HCT.

Main Methods:

• Review of existing literature on MHC class II deficiency and HCT outcomes.
• Analysis of immunological assessments and diagnostic criteria.
• Discussion of therapeutic strategies and transplant optimization.

Main Results:

• HCT is the only curative therapy, but challenging due to comorbidities.
• Optimized HCT protocols have improved survival rates in affected children.
• Post-HCT patients show restored antigen-specific responses despite persistent CD4+ T-lymphopenia.

Conclusions:

• Modern HCT approaches have significantly improved outcomes for MHC class II deficiency.
• Long-term monitoring and multi-center studies are crucial for understanding transplant survival and disease trajectory.